Identifikasi Determinan Molekul Interaksi STK630921 pada Interleukin-17A

Article Sidebar

PDF (Bahasa Indonesia)
Published: Jul 29, 2022
DOI: https://doi.org/10.25077/jsfk.9.1.57-63.2022
Keywords:
determinan molekul, STK 630921, Interleukin-17A

Main Article Content

Fransiscus Deddy Riandono
Fakultas Farmasi Universitas Sanata Dharma
Enade Perdana Istyastono
Fakultas Farmasi Universitas Sanata Dharma
https://orcid.org/0000-0002-8344-5587

Abstract

Interleukin-17A (IL-17A) merupakan sitokin pro-inflamasi yang terlibat dalam patogenesis beberapa penyakit, antara lain psoriasis, rheumatoid arthritis, kanker, diabetes dan penyakit ginjal stadium akhir. Peningkatan kadar serum IL-17A memberikan petunjuk adanya keterkaitan antara IL-17A pada kejadian nefropati diabetik. Keterkaitan ini juga diperjelas dengan temuan bahwa penghambatan aktivitas IL-17A dapat menurunkan albuminuria, cedera ginjal dan menunda perkembangan nefropati diabetik. Peranan IL-17A ini menjadikannya sebagai pilihan target potensial terapi nefropati diabetik yang sejauh ini bertumpu pada pengendalian optimal sistem renin angiotensin. Penelitian ini bertujuan mengidentifikasi determinan molekul interaksi STK630921 pada IL-17A. Penelitian dilakukan dengan penambatan molekul STK630921 pada protein IL-17A, dilanjutkan dengan simulasi dinamika molekul selama 15 ns. Identifikasi determinan molekul dilakukan menggunakan bantuan perangkat lunak PyPLIF-HIPPOS terhadap hasil simulasi dinamika molekul. Penelitian ini berhasil mengidentifikasikan asam-asam amino yang berperan penting yaitu His29, Trp67, Asn27, Lys114 dan Glu95 dengan interaksi aromatik dan interaksi hidrogen sebagai jenis interaksi yang berperan pada aktivitas STK630921 pada struktur protein 4HR9.

Article Details

How to Cite
Riandono, F. D., & Istyastono, E. P. (2022). Identifikasi Determinan Molekul Interaksi STK630921 pada Interleukin-17A. Jurnal Sains Farmasi & Klinis, 9(1), 57–63. https://doi.org/10.25077/jsfk.9.1.57-63.2022
Issue
Vol. 9 No. 1 (2022): J Sains Farm Klin 9(1), April 2022
Section
Research Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.

References

Ma J, Li YJ, Chen X, Kwan T, Chadban SJ, Wu H. Interleukin 17A promotes diabetic kidney injury. Sci Rep. 2019;9(1):1–12. https://doi.org/10.1038/s41598-019-38811-4

Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90. https://doi.org/10.1007/s12016-018-8702-3

Robert M, Miossec P. IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels. Front Med. 2019;6(JAN):1–10. https://doi.org/10.3389/fmed.2018.00364

Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim H-Y. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 2012;33(4):931–6. https://doi.org/10.1093/carcin/bgs106

Kuriya G, Uchida T, Akazawa S, Kobayashi M, Nakamura K, Satoh T, et al. Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia. 2013;56(8):1773–80. https://doi.org/10.1007/s00125-013-2935-8

Coto E, Gómez J, Suárez B, Tranche S, Díaz-Corte C, Ortiz A, et al. Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort. Hum Immunol. 2015;76(2–3):75–8. https://doi.org/10.1016/j.humimm.2015.01.027

Baharlou R, Ahmadi-Vasmehjani A, Davami MH, Faraji F, Atashzar MR, Karimipour F, et al. Elevated Levels of T-helper 17-associated Cytokines in Diabetes Type I Patients: Indicators for Following the Course of Disease. Immunol Invest. 2016;45(7):641–51. https://doi.org/10.1080/08820139.2016.1197243

Zhang N, Tai J, Qu Z, Zhang Z, Zhao S, He J, et al. Increased CD4(+)CXCR5(+)T follicular helper cells in diabetic nephropathy. Autoimmunity. 2016;49(6):405–13. https://doi.org/10.1080/08916934.2016.1196677

Lavoz C, Matus YS, Orejudo M, Carpio JD, Droguett A, Egido J, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney Int. 2019;95(6):1418–32. https://doi.org/10.1016/j.kint.2018.12.031

Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J nephropharmacology. 2016;5(1):49–56.

Cheng HT, Xu X, Lim PS, Hung KY. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015. Diabetes Care. 2021;44(1):89–97. https://doi.org/10.2337/dc20-1913

Coates PT, Devuyst O, Wong G, Okusa M, Oliver J, York N, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4):S1–115. https://doi.org/10.1016/j.kint.2020.06.019

Suyama K, Sakai D, Watanabe M, Hirayama N, Nakamura Y. Effects of interleukin †17A in nucleus pulposus cells and its small †molecule inhibitors for intervertebral disc disease. 2018;(April):5539–51. https://doi.org/10.1111/jcmm.13828

Lieu R, Antonysamy S, Druzina Z, Ho C, Kang NR, Pustilnik A, et al. Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. PLoS One. 2020;15(9 September):1–16. https://doi.org/10.1371/journal.pone.0232311

Krieger E, Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem. 2015;36(13):996–1007. https://doi.org/https://doi.org/10.1002/jcc.23899

Istyastono EP, Radifar M, Yuniarti N, Prasasty VD, Mungkasi S. PyPLIF HIPPOS: A Molecular Interaction Fingerprinting Tool for Docking Results of AutoDock Vina and PLANTS. J Chem Inf Model. 2020;60(8):3697–702. https://doi.org/10.1021/ACS.JCIM.0C00305

Istyastono EP, Yuniarti N, Prasasty VD, Mungkasi S. Pyplif hippos-assisted prediction of molecular determinants of ligand binding to receptors. Molecules. 2021;26(9):1–12. https://doi.org/10.3390/molecules26092452

Liu K, Watanabe E, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J Comput Aided Mol Des. 2017;31(2):201–11. https://doi.org/10.1007/s10822-016-0005-2

Liu K, Kokubo H. Exploring the Stability of Ligand Binding Modes to Proteins by Molecular Dynamics Simulations: A Cross-docking Study. J Chem Inf Model. 2017;57(10):2514–22. https://doi.org/10.1021/ACS.JCIM.7B00412

Prasasty VD, Istyastono EP. Structure-Based Design and Molecular Dynamics Simulations of Pentapeptide AEYTR as a Potential Acetylcholinesterase Inhibitor. Indones J Chem. 2020;20(4):953–9. https://doi.org/10.22146/IJC.46329